These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 18284938)

  • 1. Heparin and low molecular weight heparins as scaffolds for assembling antithrombin and serine proteases.
    Ofosu FA
    Thromb Res; 2008; 123(1):5-7. PubMed ID: 18284938
    [No Abstract]   [Full Text] [Related]  

  • 2. [Anticoagulant activity of low-molecular-weight heparins obtained using a hydrolase complex].
    Drozd NN; Tolstenkov AS; Bannikova GE; Miftakhova NT; Lapikova ES; Makarov VA; Varlamov VP
    Eksp Klin Farmakol; 2007; 70(6):19-24. PubMed ID: 18318190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biochemistry and pharmacology of low molecular weight heparin.
    Rosenberg RD
    Semin Hematol; 1997 Oct; 34(4 Suppl 4):2-8. PubMed ID: 9399404
    [No Abstract]   [Full Text] [Related]  

  • 4. The activity of unfractionated heparin and low molecular weight heparins in rabbit plasma--the need for using absolute anti-factor Xa and antithrombin activities.
    Peyrou V; Béguin S; Boneu B; Hemker HC
    Thromb Haemost; 1997 Feb; 77(2):312-6. PubMed ID: 9157588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Covalent antithrombin-heparin complexes.
    Patel S; Berry LR; Chan AK
    Thromb Res; 2007; 120(2):151-60. PubMed ID: 16978685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of sulfation on antithrombin-thrombin/factor Xa interactions in semisynthetic low molecular weight heparins.
    Sissi C; Naggi A; Torri G; Palumbo M
    Semin Thromb Hemost; 2001 Oct; 27(5):483-7. PubMed ID: 11668417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heparin and low molecular weight heparin in thrombosis and beyond.
    Mousa SA
    Curr Opin Investig Drugs; 2002 Aug; 3(8):1181-6. PubMed ID: 12211411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [From heparin to synthetic antithrombotic oligosaccharides].
    Petitou M
    Bull Acad Natl Med; 2003; 187(1):47-56; discussion 56-7. PubMed ID: 14556453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heparin chain-length dependence of factor Xa inhibition by antithrombin in plasma.
    Rezaie AR
    Thromb Res; 2007; 119(4):481-8. PubMed ID: 16515805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism of low-molecular-weight heparin reversal by platelet factor 4.
    Fiore MM; Mackie IM
    Thromb Res; 2009 May; 124(1):149-55. PubMed ID: 19195682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An algal sulfated galactan has an unusual dual effect on venous thrombosis due to activation of factor XII and inhibition of the coagulation proteases.
    Melo FR; Mourão PA
    Thromb Haemost; 2008 Mar; 99(3):531-8. PubMed ID: 18327401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of antithrombin-protease interactions by semisynthetic low-molecular-weight heparins with different sulfation patterns.
    Sissi C; Naggi A; Torri G; Palumbo M
    Semin Thromb Hemost; 2003 Dec; 29(6):661-70. PubMed ID: 14719183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New antithrombin-based anticoagulants.
    Desai UR
    Med Res Rev; 2004 Mar; 24(2):151-81. PubMed ID: 14705167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heparin and low-molecular-weight heparin.
    Gray E; Mulloy B; Barrowcliffe TW
    Thromb Haemost; 2008 May; 99(5):807-18. PubMed ID: 18449410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overview: from heparin to low molecular weight heparin: beyond anticoagulation.
    Mousa SA; Fareed J
    Curr Opin Investig Drugs; 2001 Aug; 2(8):1077-80. PubMed ID: 11892916
    [No Abstract]   [Full Text] [Related]  

  • 16. Linear diffusion of thrombin and factor Xa along the heparin molecule explains the effects of extended heparin chain lengths.
    Wagenvoord R; Al Dieri R; van Dedem G; Béguin S; Hemker HC
    Thromb Res; 2008; 122(2):237-45. PubMed ID: 18045667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The importance of anti-factor Xa and antithrombin activities of low molecular weight heparins.
    Lane DA; Ryan K
    J Lab Clin Med; 1990 Aug; 116(2):269-70. PubMed ID: 2394942
    [No Abstract]   [Full Text] [Related]  

  • 18. [Natural and synthetic glycosaminoglycans. Molecular characteristics as the basis of distinct drug profiles].
    Alban S
    Hamostaseologie; 2008 Feb; 28(1-2):51-61. PubMed ID: 18278163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A synthetic antithrombin III binding pentasaccharide is now a drug! What comes next?
    Petitou M; van Boeckel CA
    Angew Chem Int Ed Engl; 2004 Jun; 43(24):3118-33. PubMed ID: 15199558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of new heparin-like compounds and other antithrombotic drugs and their interaction with vascular endothelial cells.
    Nader HB; Pinhal MA; Baú EC; Castro RA; Medeiros GF; Chavante SF; Leite EL; Trindade ES; Shinjo SK; Rocha HA; Tersariol IL; Mendes A; Dietrich CP
    Braz J Med Biol Res; 2001 Jun; 34(6):699-709. PubMed ID: 11378657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.